Residual Risk for Coronary Heart Disease Events and Mortality Despite Intensive Medical Management Following Myocardial Infarction

High-intensity statins, beta-blockers, angiotensin converting enzyme inhibitors, angiotensin receptor blockers, and antiplatelet agents (i.e. intensive medical management) reduce coronary heart disease (CHD) risk following myocardial infarction (MI).
Source: Journal of Clinical Lipidology - Category: Lipidology Authors: Tags: Original Research Source Type: research

Related Links:

Authors: Alwi I Abstract Over more than two decades, the concept of atherosclerosis has developed and lead to inflammatory hypothesis. Inflammation plays an important role on pathogenesis of atherothrombosis and coronary heart disease (CHD), including acute coronary syndrome (ACS). Although the management of ACS has been demonstrated to be beneficial for secondary prevention of coronary heart disease (such as using statin and aspirin) and also seemed to have positive effect on inflammation, the identification of effective management, specifically targeting inflammation, has been not been comprehensively understood....
Source: Acta medica Indonesiana - Category: Internal Medicine Tags: Acta Med Indones Source Type: research
High-intensity statins, beta-blockers, angiotensin-converting enzyme inhibitors, angiotensin receptor blockers, and antiplatelet agents (ie, intensive medical management) reduce coronary heart disease (CHD) risk after myocardial infarction (MI).
Source: Journal of Clinical Lipidology - Category: Lipidology Authors: Tags: Original Article Source Type: research
AbstractPurpose of ReviewTo review randomized interventional clinical and imaging trials that support lower targeted atherogenic lipoprotein cholesterol goals in “extreme” and “very high” atherosclerotic cardiovascular disease (ASCVD) risk settings. Major atherosclerotic cardiovascular event (MACE) prevention among the highest risk patients with ASCVD requires aggressive management of global risks, including lowering of the fundamental atherogenic ap olipoprotein B-associated lipoprotein cholesterol particles [i.e., triglyceride-rich lipoprotein remnant cholesterol, low-density lipoprotein cholester...
Source: Current Diabetes Reports - Category: Endocrinology Source Type: research
Diagnoses increase but gender gap in treatment persist Related items fromOnMedica Coronary heart disease remains UK ’s biggest killer Glucosamine supplements may reduce stroke risk The new GP contract: transforming primary care, transforming CVD prevention Statins halve heart attack and stroke risk in healthy adults More Scottish GPs needed to fight heart disease
Source: OnMedica Latest News - Category: UK Health Source Type: news
This study aimed to investigate the impact of clinical pharmacist intervention on the prognosis of acute coronary syndrome (ACS) in Chinese patients with CHD. Two hundred and forty patients who had ACS were recruited. Participants were randomly assigned to the intervention group (n = 120) or the control group (n = 120). The intervention group received a medication assessment and education by the clinical pharmacist at discharge and telephone follow-ups at 1 week and 1 and 3 months after discharge. The control group received usual care. The primary outcomes of this study were the proportion of patients who had major adverse...
Source: Frontiers in Pharmacology - Category: Drugs & Pharmacology Source Type: research
Stopping statins raises heart attack risk by almost half for over 75s, researchers find Related items fromOnMedica Glucosamine supplements may reduce stroke risk Vitamin D supplements do not confer cardiovascular protection Gestational diabetes raises long-term CVD risk Coronary heart disease remains UK ’s biggest killer Heart disease and stroke deaths plummet in Scotland
Source: OnMedica Latest News - Category: UK Health Source Type: news
Publication date: Available online 1 July 2019Source: The Lancet Diabetes &EndocrinologyAuthor(s): Kausik K Ray, Helen M Colhoun, Michael Szarek, Marie Baccara-Dinet, Deepak L Bhatt, Vera A Bittner, Andrzej J Budaj, Rafael Diaz, Shaun G Goodman, Corinne Hanotin, Robert A Harrington, J Wouter Jukema, Virginie Loizeau, Renato D Lopes, Angèle Moryusef, Jan Murin, Robert Pordy, Arsen D Ristic, Matthew T Roe, José TuñónSummaryBackgroundAfter acute coronary syndrome, diabetes conveys an excess risk of ischaemic cardiovascular events. A reduction in mean LDL cholesterol to 1·4–1·...
Source: The Lancet Diabetes and Endocrinology - Category: Endocrinology Source Type: research
Authors: Alves-Ferreira J, Rocha-Neves J, Dias-Neto M, F Braga S Abstract Objetives: Carotid endarterectomy (CEA) is an established treatment for carotid stenosis (CS). However, this procedure is not risk-free and it is insufficient to control disseminated atherosclerosis. Our aim was to determine long-term cardiovascular (CV) morbidity and mortality after CEA and identify associated risk predictors. DESIGN: Consecutive cohorts of CEAs performed between 2010-2018 in two Portuguese hospitals were retrospectively analysed. The major end-points were acute myocardial infarction (AMI), stroke, all-cause death and ma...
Source: Scandinavian Cardiovascular Journal - Category: Cardiology Tags: Scand Cardiovasc J Source Type: research
This study determine the relative treatment effects of NST on fatal and nonfatal CV events among statin-treated patients. Methods A network meta-analysis based on a systematic review of randomized controlled trials (RCTs) comparing non-statin lipid-modifying agents among statin-treated patients was performed. PubMed, EMBASE, CENTRAL, and Clinicaltrial.gov were searched up to April 10, 2018. The primary outcomes were CV and all-cause mortalities. Secondary CV outcomes were coronary heart disease (CHD) death, non-fatal myocardial infarction (MI), any stroke, and coronary revascularization. Risks of discontinuations were ...
Source: Frontiers in Pharmacology - Category: Drugs & Pharmacology Source Type: research
Sarah K. Azzam1, Wael M. Osman2, Sungmun Lee1, Kinda Khalaf1, Ahsan H. Khandoker1, Wael Almahmeed3,4, Herbert F. Jelinek5 and Habiba S. Al Safar1,2* 1Biomedical Engineering Department, Khalifa University of Science and Technology, Abu Dhabi, United Arab Emirates 2Khalifa University Center of Biotechnology, Abu Dhabi, United Arab Emirates 3Institute of Cardiac Science, Sheikh Khalifa Medical City, Abu Dhabi, United Arab Emirates 4Heart and Vascular Institute, Cleveland Clinic, Abu Dhabi, United Arab Emirates 5Australian School of Advanced Medicine, Sydney and School of Community Health, Charles Sturt University, Ma...
Source: Frontiers in Endocrinology - Category: Endocrinology Source Type: research
More News: Beta-Blockers | Cardiology | Cholesterol | Coronary Heart Disease | Heart | Heart Attack | Heart Disease | Lipidology | Statin Therapy